Bristol-Myers Squibb and Pfizer have hit another costly snag in their quest to gain an FDA approval for Eliquis (apixaban), their blockbuster anti-clotting hopeful.
An influential pharma analyst downgraded Merck shares, saying they've hit their price ceiling. Why? The reasons can be summed up in four drugs: Singulair, Gardasil, taranabant, and Vytorin. Sanford
Speculation that Bristol-Myers Squibb might be a takeover target -- that's old news. Informed speculation based on certain strategic moves BMS has made recently -- worth passing on. Tim Anderson, the